Status:
UNKNOWN
A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication
Lead Sponsor:
Ruth M. Rothstein CORE Center
Collaborating Sponsors:
Virco
Conditions:
HIV-1
HIV Infections
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The investigators seek to determine whether Virco®TYPE HIV-1 provides benefits equivalent to those provided by local expert review. The investigators propose that clinic patients of the Ruth M. Rothst...
Detailed Description
Patients having some documented genotypic HIV resistance but having more than one fully active medication will be randomized to either local review or algorithmic review by VircoType HIV-1.
Eligibility Criteria
Inclusion
- HIV resistance testing that demonstrates resistance to at least one drug
- Patients of the CORE Center, Chicago Illinois
Exclusion
- Wild type HIV on resistance testing or less than or equal to one active antiretroviral medication
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2012
Estimated Enrollment :
756 Patients enrolled
Trial Details
Trial ID
NCT00840762
Start Date
March 1 2009
End Date
July 1 2012
Last Update
January 26 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ruth M. Rothstein CORE Center
Chicago, Illinois, United States, 60612